Energy News / Shareholders Foundation, Inc.

Ophthotech Corp Now IVERIC Bio, Inc (NASDAQ: OPHT, Now NASDAQ: ISEE) Long Term Investor Alert: Investigation of Potential Wrongdoing

Via: ReleaseWire

Updated 11:15 AM CDT, Mon, September 30,2019

An investigation on behalf of current long term investors in Ophthotech Corp now IVERIC bio, Inc (NASDAQ: OPHT, now NASDAQ: ISEE) shares over possible breaches of fiduciary duty by certain officers and directors was announced.

San Diego, CA -- (SBWIRE) -- 09/30/2019 -- An investigation was announced for long time investors in shares of Ophthotech Corp now IVERIC bio, Inc (NASDAQ: OPHT, now NASDAQ: ISEE) concerning potential breaches of fiduciary duties by certain directors of Ophthotech Corp now IVERIC bio, Inc.

Investors who are current long term investors in Ophthotech Corp now IVERIC bio, Inc (NASDAQ: OPHT, now NASDAQ: ISEE) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for investors in NASDAQ: OPHT, now NASDAQ: ISEE stocks follows a lawsuit filed against Ophthotech Corp now IVERIC bio, Inc over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: OPHT, now NASDAQ: ISEE stocks, concerns whether certain Ophthotech Corp now IVERIC bio, Inc directors are liable in connection with the allegations made in that lawsuit.

The plaintiff alleges that Ophthotech made allegedly overtly positive representations about the effectiveness and potential of its treatment Fovista when used in combination with Lucentis, a commercially available anti-vascular endothelial growth factor agent, despite awareness that the phase 3 clinical trial of Fovista would fail to achieve its primary endpoint of change in best corrected visual acuity from baseline at 12 months over Lucentis alone.

Ophthotech Corp reported that its annual Total Revenue rose from $41.26 million in 2014 to $51.56 million in 2015 and that its Net Loss declined from $116.77 million in 2014 to $105.72 million in 2015.

Those who purchased shares of Ophthotech Corp now IVERIC bio, Inc (NASDAQ: OPHT, now NASDAQ: ISEE) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

For more information on this press release visit:
http://www.sbwire.com/press-releases/ophthotech-corp-now-iveric-bio-inc-nasdaq-opht-now-nasdaq-isee-long-term-investor-alert-investigation-of-potential-wrongdoing-1261431.htm

Media Relations Contact
Michael Daniels
1-858-779-1554
Email: Click to Email Michael Daniels
Web: http://www.ShareholdersFoundation.com